



ORIGINAL ARTICLE

## Chromosomal microarrays testing in children with developmental disabilities and congenital anomalies<sup>☆</sup>



Guillermo Lay-Son<sup>a,b,\*</sup>, Karena Espinoza<sup>a</sup>, Cecilia Vial<sup>a</sup>, Juan C. Rivera<sup>a</sup>,  
María L. Guzmán<sup>a,b</sup>, Gabriela M. Repetto<sup>a,b</sup>

<sup>a</sup> Center for Human Genetics, Facultad de Medicina, Clínica Alemana Universidad del Desarrollo, Santiago, Chile

<sup>b</sup> Hospital Padre Hurtado, Santiago, Chile

Received 20 March 2014; accepted 9 July 2014

Available online 30 October 2014

### KEYWORDS

Microarrays;  
Congenital anomalies;  
Developmental disabilities;  
Copy number variants;  
Diagnosis

### Abstract

**Objectives:** Clinical use of microarray-based techniques for the analysis of many developmental disorders has emerged during the last decade. Thus, chromosomal microarray has been positioned as a first-tier test. This study reports the first experience in a Chilean cohort.

**Methods:** Chilean patients with developmental disabilities and congenital anomalies were studied with a high-density microarray (CytoScan™ HD Array, Affymetrix, Inc., Santa Clara, CA, USA). Patients had previous cytogenetic studies with either a normal result or a poorly characterized anomaly.

**Results:** This study tested 40 patients selected by two or more criteria, including: major congenital anomalies, facial dysmorphism, developmental delay, and intellectual disability. Copy number variants (CNVs) were found in 72.5% of patients, while a pathogenic CNV was found in 25% of patients and a CNV of uncertain clinical significance was found in 2.5% of patients.

**Conclusion:** Chromosomal microarray analysis is a useful and powerful tool for diagnosis of developmental diseases, by allowing accurate diagnosis, improving the diagnosis rate, and discovering new etiologies. The higher cost is a limitation for widespread use in this setting.

© 2014 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. All rights reserved.

<sup>☆</sup> Please cite this article as: Lay-Son G, Espinoza K, Vial C, Rivera JC, Guzmán ML, Repetto GM. Chromosomal microarrays testing in children with developmental disabilities and congenital anomalies. J Pediatr (Rio J). 2015;91:189–95.

\* Corresponding author.

E-mail: [glayson@udd.cl](mailto:glayson@udd.cl) (G. Lay-Son).

**PALAVRAS-CHAVE**

Microarrays;  
Anomalias  
congênitas;  
Atraso de  
desenvolvimento;  
Variante do número  
de cópia;  
Diagnóstico

## Análise cromossômica por microarray em crianças com deficiências de desenvolvimento e anomalias congênitas

**Resumo**

**Objetivo:** O uso clínico de técnicas baseadas em microarrays para a análise de transtornos de desenvolvimento tem surgido durante a última década. Assim, o microarray cromossômico tem sido posicionado como um teste de primeiro nível clínico. Relatamos a primeira experiência em uma coorte chilena.

**Métodos:** Pacientes chilenos com atraso de desenvolvimento e anomalias congênitas foram estudados com um microarray de alta densidade (CytoScan™ HD Array, Affymetrix, Inc., Santa Clara, CA, EUA). Pacientes tiveram estudos citogenéticos anteriores, ou um resultado normal ou de uma anomalia não bem caracterizada.

**Resultados:** Foram analisados 40 pacientes selecionados por dois ou mais critérios, incluindo: anomalias congênitas maiores, dismorfismo facial, atraso de desenvolvimento e deficiência intelectual. Uma variante do número de cópia (CNV) foi encontrada em 72,5% dos pacientes, enquanto que uma CNV patogênica foi encontrada em 25% dos pacientes e uma CNV de significado clínico incerto foi encontrada em 2,5% dos pacientes.

**Conclusões:** A análise cromossômica microarray é uma ferramenta útil e poderosa em transtornos de desenvolvimento, permitindo um diagnóstico preciso, melhorando a taxa de diagnóstico, e descobrindo novas etiologias. O custo mais elevado é uma limitação para um uso difundido em nossa realidade.

© 2014 Sociedade Brasileira de Pediatria. Publicado por Elsevier Editora Ltda. Todos os direitos reservados.

**Introduction**

Major congenital anomalies affect two to three of every 100 live newborns, and are a leading cause of infant mortality and disability.<sup>1,2</sup> Although most are isolated and multifactorial in origin, patients with multiple abnormalities require an assessment to identify an underlying genetic cause.

In recent years, the etiological study of developmental disorders has been enriched with the clinical use of microarray-based techniques. In developed countries, molecular karyotyping or chromosomal microarray (CMA) is considered the first-line technique for the analysis of patients with multiple congenital anomalies, nonsyndromic developmental delay/intellectual disability, and autism spectrum disorders.<sup>3-7</sup>

In contrast, in developing nations such as Latin American countries, detection of chromosomal anomalies is still performed mainly by conventional cytogenetic techniques. GTG (G-bands by trypsin using Giemsa) banding karyotyping in lymphocytes has been mainly used to identify chromosomal abnormalities with a resolution equal or greater than 5-10 megabases (5-10 Mb).<sup>8-11</sup> Fluorescent *in situ* hybridization (FISH) is available for a limited number of diseases caused by chromosomal microdeletions/microduplications and has a resolution of 2-5 Mb in metaphase and between 50-150 Kb in interphase nuclei.<sup>8,9,11-13</sup> Other molecular techniques have been developed to look for small microdeletions/microduplications, such as multiplex ligation-dependent probe amplification (MLPA).<sup>14</sup> In contrast to these conventional techniques, CMA has a higher resolution, which reaches up to 50 Kb, a ten times higher resolution than conventional karyotyping.<sup>13,15</sup> It seeks genetic imbalances (gains or losses of chromosomal

segments) across the genome and has allowed the identification of new syndromes that are not readily detected by the methods described above.<sup>16-18</sup> The discovery of normal variation as copy number variations (CNVs) poses a challenge for the clinical interpretation.<sup>15</sup>

Whilst diagnostic studies for individuals with congenital anomalies or intellectual disability based on conventional cytogenetics have a diagnostic yield close to 3%, CMA has a yield of around 15% to 20%, over five times greater than G-banded karyotype,<sup>6</sup> justifying its use as a first line diagnostic test for patients with an unknown clinical diagnosis. It is estimated that CMA alone is capable of detecting over 99% of all karyotype abnormalities.<sup>5</sup>

This report presents the authors' pioneering experience in the use of CMA in a cohort of Chilean patients with multiple congenital anomalies without etiological diagnosis.

**Methods****Patients**

Forty patients were selected from the Genetic Clinics at Hospital Padre Hurtado (Santiago, Chile), between May of 2012 and November of 2012.

This study included patients who had at least two of the following clinical features: major congenital anomalies (MCAs), facial dysmorphism (FD), developmental delay (DD), or intellectual disability (ID). All patients lacked a definite cause for the disorder.

Of all patients, 36 had a normal karyotype, two patients had an uncharacterized small additional marker chromosome (sSMC), one had a derivative chromosome, one had an

inherited Robertsonian translocation, and one patient had monosomy X, but with unusual additional features.

The local ethics committee approved this study, and written informed consent was obtained from all patients and/or parents/guardians.

### Sample Processing

Genomic DNA was purified from peripheral blood mononuclear cells with AxyPrep Blood Genomic DNA Miniprep Kit (Axygen Biosciences, Union City, CA, USA) following manufacturer's instructions. Genomic DNA of each patient was hybridized with the CytoScan™ HD Array (Affymetrix, Inc., Santa Clara, CA, USA) according to manufacturer's instructions. This is a custom high-density comparative genomic hybridization array with almost 2.7 million of genetic markers, includes 700,000 single nucleotide polymorphism (SNP) markers and over 1.9 oligonucleotide non-polymorphic probes for CNV detection.

### Data Analysis

Array data were analyzed using the Affymetrix® Chromosome Analysis Software Suite (ChAS) v.1.2.2 (Affymetrix, Inc., Santa Clara, CA, USA) based on the reference genome sequence of the UCSC Genome Browser hg19, Feb. 2009 (GRCh37/hg19). The authors analyzed CNVs over 400 Kb as recommended.<sup>6</sup> With this higher-resolution platform, it was possible to evaluate smaller CNVs, but no patient had clinically relevant abnormalities between 100 and 400 Kb, so this limit was kept for purposes of this report. CNVs over 400 Kb were categorized by clinical significance as CNV of clear clinical relevance (group 1), CNV of unclear relevance or uncertain significance (group 2), or benign or polymorphic CNV (group 3), using the publicly available databases ISCA (International Standard Cytogenomic Array),<sup>19</sup> DGV (Database of Genomic Variants),<sup>20,21</sup> OMIM (Online Mendelian Inheritance in Man),<sup>22</sup> DECIPHER (Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources)<sup>23,24</sup> and ECARUCA (European Cytogeneticists Association Register of Unbalanced Chromosome Aberrations).<sup>25</sup>

### Results

Of the 40 patients analyzed, 16 (41%) were female. Ages ranged from 1 month to 25 years, with a median age of 4.2 years. As selected, the vast majority of the patients have multiple anomalies, including structural and functional developmental disorders. Clinical details are summarized in Table 1.

#### CNV characterization (Fig. 1)

Fifty-five CNVs over 400 Kb were observed in 29 of 40 patients (72.5%), ranging between 0 and 4 CNVs per patient. Of the total, 11 were losses and 44 were gains (Fig. 1A). The size of chromosomal imbalances ranged from 420.9 Kb to 25.2 Mb. The latter corresponded to one patient with an sSMC detected by karyotype.

These 55 CNVs were classified into three groups based on their clinical interpretation.

According to the classification adopted (Fig. 1B), 21.8% belonged to group 1 (clear clinical relevance related to the phenotype), 1.8% to group 2 (unclear relevance), and 76.4% to group 3 (benign or polymorphic). Losses were predominant in group 1, while gains were predominant in group 3.

### Diagnostic yield

In Group 1, two patients had two terminal chromosome imbalances, each probably derived from unbalanced cryptic translocations. Seven patients had a microdeletion and one patient had a mosaic partial trisomy 20 (one of the patients had an sSMC). More details are summarized in Table 1.

In Group 2, only one patient had a variant of uncertain significance (VOUS).<sup>26</sup> This patient had a 2 Mb triplication at 9p23 [arr 9p23(9,323,653-11,359,708)x3], but with the information available in the databases and in biomedical literature, a definitive pathogenic effect could not be ruled out or assigned.

The authors failed to find true genetic imbalances in the second patient with an sSMC and the patient with a derivative chromosome 16. In the patient with the Robertsonian translocation, no genomic imbalance that explained the phenotype was found. Finally, in the patient with monosomy X, the deletion of one X was confirmed, but additional genomic imbalances were not found (Table 1).

### Clinical interpretation

This study found a pathogenic CNV that was not previously observed by ( $n = 9$ ) or not well characterized ( $n = 1$ ) by conventional karyotype in ten of 40 patients of group 1 (25.0%). In addition, a known cytogenetic anomaly in one patient was corroborated (monosomy X).

If only the patients with normal karyotype are considered (35 patients), the diagnosis rate increased to 28.5%.

Additionally, this study found a CNV of uncertain clinical significance or VOUS (group 2) in one additional patient. This patient is waiting for additional testing and follow up to define the clinical relevance of this finding. It is planned to study both parents with FISH and/or MLPA.

### Discussion


This is the first report of the CMA testing in a cohort of Chilean patients with developmental disabilities, considering that there are few studies of the clinical use of chromosomal microarrays in Latin America, as experiences of individual cases are the norm. Within South America, a similar experience was reported with a group of patients from Brazil.<sup>27,28</sup> Those authors analyzed 95 syndromic patients with normal karyotypes and reported a diagnostic yield of 17%.<sup>28</sup>

The present study detected over 25% pathogenic alterations in this cohort, which is in the upper range that has been reported in the literature. In patients with syndromic and nonsyndromic developmental delay/intellectual

**Table 1** Summary of clinical features and genetic imbalances found in this cohort.

Patient ID	Developmental Delay	Intellectual Disability	Generalized hypotonia	Seizures	Central nervous system malformation	Microcephaly	Facial dysmorphism	Congenital eye anomaly	Visual anomaly	External ear anomaly	Hearing defect	Cleft lip +/-palate	Cleft palate/Robin sequence	Congenital heart disease	Hemivertebrae/Scoliosis	Gastrointestinal malformation	Abdominal hernia	Kidney malformation	Genital/Urinary tract defect	Limb anomaly	Generalized ligamentous hyperlaxity	Skeletal anomaly	Short stature	Failure to thrive	Obesity	Congenital Skin Defect	Cytogenetic studies	CMA results	Clinical Interpretation
1		N/A																								46,XX	arr(1-22,X)x2	No genomic imbalances	
2		N/A																									46,XX	arr(1-22,X)x2	No genomic imbalances
3		N/A																									46,XX	arr(1-22,X)x2	No genomic imbalances
4		N/A																									46,XY	arr(1-22)x2,(XY)x1	No genomic imbalances
5																											46,XY	arr(1-22)x2,(XY)x1	No genomic imbalances
6		N/A																									46,XY	arr 9p23(9,323,653 - 11,359,708)x3	Variant of unknown significance (VUOS)
7		N/A																									46,XY	arr(1-22)x2,(XY)x1	No genomic imbalances
8																											46,XX; FISH22q (-)	arr 6p25.1-p23(6,389,847-15,124,349)x1	6p25.1p23 deletion
9		N/A																									46,XX	arr(1-22,X)x2	No genomic imbalances
10																											46,XY,der(16)	arr(1-22)x2,(XY)x1	Pericentric inversion 16
11		N/A																									46,XY	arr(1-22)x2,(XY)x1	No genomic imbalances
12		N/A																									46,XY	arr(1-22)x2,(XY)x1	No genomic imbalances
13																											46,XX; FISH22q (-)	arr(1-22,X)x2	No genomic imbalances
14																											46,XX	arr(1-22,X)x2	No genomic imbalances
15																											46,XY; FISH22q (-)	arr(1-22)x2,(XY)x1	No genomic imbalances
16		N/A																									46,XY	arr(1-22)x2,(XY)x1	No genomic imbalances
17																											46,XY	arr(1-22)x2,(XY)x1	No genomic imbalances
18																											46,XX	arr(1-22,X)x2	No genomic imbalances
19																											47,XX,+mar/46,XX	arr 20p12.3q11.22(7,180,552-32,402,789)x2-3	Partial trisomy 20 mosaicism
20		N/A																									46,XY	arr 2q23.2q24.2(150,216,033-161,228,203)x1	2q23.2q24.3 deletion
21																											46,XY; FISH22q (-)	arr(1-22)x2,(XY)x1	No genomic imbalances
22																											46,XY; FISH22q (-)	arr 15q25.2(83,083,418-84,834,123)x1	15q25.2 deletion
23																											46,XY; FISH22q (-)	arr(1-22)x2,(XY)x1	No genomic imbalances
24		N/A																									46,XY	arr(1-22)x2,(XY)x1	No genomic imbalances
25																											46,XX; FISH17p (-)	arr(1-22,X)x2	No genomic imbalances
26																											46,XX	arr(1-22,X)x2	No genomic imbalances
27		N/A																									46,XY	arr(1-22)x2,(XY)x1	No genomic imbalances
28		N/A																									46,XY; FISH22q (-); Chromosome breakage analysis (-)	arr(1-22)x2,(XY)x1	No genomic imbalances
29																											46,XX	arr(1-22,X)x2	No genomic imbalances
30																											45,XY,der(14;15)(q10;q10)	arr(1-22)x2,(XY)x1	Robertsonian translocation, no genomic imbalances
31																											46,XX	arr 22q12.1q12.3(28,966,333-34,541,402)x1	22q12.1q12.3 deletion
32		N/A																									47,XX,+mar (mat); FISH15q (-)	arr(1-22,X)x2	SMC bisatellited (NOR staining), heterochromatin maternally derived (healthy mother)
33		N/A																									46,XX; FISH22q (-)	arr(1-22,X)x2	No genomic imbalances
34																											46,XY; FISH7q (-), 22q(-) subtelomeres (-)	arr 6p25.3 -p25.2(156,974-2,400,023)x1	6p25.3p25.2 deletion
35		N/A																									46,XY	arr 6p25.3p25.2(294,910-3,403,875)x3,12p13.33(173,786-3,283,049)x1	12p13.33 deletion; 6p25.3p25.2 triplication
36																											46,XY	arr 14q32.12q32.33(94,174,317-107,285,437)x3,22q13.31q13.33(47,852,611-51,197,838)x1	22q13 deletion; 14q32.12q32.33 triplication
37		N/A																									46,XX; FISH22q (-)	arr 4q34.1-q35.2(174,409,811-190,957,473)x1	4q34.1q35.2 deletion
38		N/A																									45,X	arr Xp22.33q28(168,546-155,233,731)x1	Monosomy X, without other imbalances
39																											46,XY	arr(1-22)x2,(XY)x1	No genomic imbalances
40																											46,XY	arr 19p13.3(3,788,725-5,346,511)x1	19p13.3 deletion

CMA, chromosomal microarray; FISH, fluorescent *in situ* hybridization; N/A, not applicable by age; NOR, nucleolar organizer region; sSMC, supernumerary small marker chromosome.



**Figure 1** Characterization of CNVs larger than 400 Kb in Chilean cohort.

A, among 40 patients, CNVs were not found in 11 individuals. In the remaining 29 patients, 55 CNVs were found (11 losses and 44 gains). B, each patient may have CNV of more than one group at a time. CNVs were categorized by clinical significance as CNV of clear clinical relevance (group 1), CNV of uncertain significance (group 2), or benign or polymorphic CNV (group 3). CNVs, copy number variants; G, gains; L, losses.

disability with normal karyotype/FISH, meta-analysis shows a diagnostic yield of 7.8%-13.8%, ranging from 5% to 50%.<sup>5,29</sup> This is largely explained by heterogeneity in the design of studies, especially in patient selection, previous testing realized, and array platforms used. In the present case, the high rate of diagnosis can be explained by the fact that the studied cohort was relatively small, had the bias of very selected patients, many of whom have remained for long time without diagnosis, and finally, used a high-density platform.

Over time, different online public databases have collected phenotypic and genomic information of thousands of anonymous patients, which allow elucidating the vast majority of CNVs as benign or polymorphic, without further analysis. In fact, the majority of this study's findings were polymorphic CNVs (copy number polymorphisms, [CNP]), corroborated in those cytogenomic databases and from the authors' own cohort data. Recurrent CNVs over 400 Kb were observed in half of these patients, mainly involving the following chromosomal loci: 10q11.22, 14q32.22, 16p11.2, 17q21.31, Yq11.223, and Yq11.23. Only one case that had a VOUS required further analysis to determine possible pathogenicity. This patient was one year and 11 months, with DD, language delay, hearing deficit, inguinal hernia, and short stature. He had a 46,XY karyotype and the array showed a 2 Mb gain in chromosome 9p23, including partial triplication of one gene: *PTPRD*. The protein *Ptpd* is a receptor-type protein-tyrosine phosphatase, is expressed in certain regions of the brain, such as the hippocampus, and could have a role in learning and memory<sup>30</sup> and the synaptic organization.<sup>31</sup> No phenotype has been assigned to the full triplication of this gene.

Although CMA is a very robust and reliable technique, it has limitations: it is unable to detect balanced genomic abnormalities such as inversions, reciprocal, and Robertsonian translocations. Depending on the platform used, low-level mosaicism and some polyploidies cannot be detected. When CMA technique is used as the first line of study, it has been described that this situation can occur in 0.78% of cases.<sup>5</sup> Finally, CMA does not give information on position of the rearrangement, FISH is often used as complementary method to identify possible rearrangements with implications for genetic counseling.<sup>7,32</sup>

In the present cohort, it was found that three patients with previously known cytogenetic abnormalities resulted in a normal molecular karyotype. As expected, the patient who is carrier for a Robertsonian translocation had a normal/balanced aCGH result. In the case of one of the two patients with sSMC, the coverage of the array, the genomic sequences involved, and the size sSMC may explain why that genetic material were undetected by this method.<sup>19</sup> Thus, this small bisatellited chromosome likely corresponds to highly repetitive sequences typical of acrocentric chromosomes not included in the array that was demonstrated by nucleolus organizer region (NOR) banding. In the patient with a derivative chromosome 16, with an abnormal banding pattern and morphology (more metacentric than usual), a pericentric inversion is the most plausible explanation.

Thus, karyotype remains more suitable to evaluate potential carriers of chromosomal rearrangements, couples with recurrent miscarriage, or patients with a distinctive aneuploidy phenotype. However, FISH is more suitable if a specific microdeletion syndrome is highly suspected.<sup>7</sup>

Chromosome microarrays are a highly accurate, robust, and high-throughput method. This study used a combined oligonucleotide-based array plus SNP array, which has many advantages, where the SNP array significantly improves the accuracy and sensitivity of the CNV detection and mosaicism, also allowing the detection of copy-neutral variants.<sup>33</sup> In the case of the chip used in this report (Cytoscan HD, Affymetrix), the platform chemistry and its algorithms analyze the oligonucleotide and SNP probes independently, and thus each CNV can be detected and confirmed at the same time, without requiring any further confirmation.<sup>32,33</sup> In this case, instead of a confirmation of the array finding, FISH analysis allows for determination of the type of rearrangement.<sup>32</sup>

A limitation for widespread use of molecular karyotype is the high cost of the test. In Chile, CMA is approximately four to seven times more expensive than a karyotype and/or FISH, and is currently not covered by health insurance. However, to reach an early diagnosis in selected patients with multiple congenital anomalies and/or global developmental delay, it can avoid unnecessary testing (the "diagnostic odyssey") and allow focusing on specific issues, which in the long term can be cost-effective.<sup>34-38</sup> It may be expected that costs will decrease over time, enabling its more widespread use. Finally, it should be mentioned that there are other platforms that have lower resolution but at a relatively reduced cost.

Recognizing its limitations, there is growing evidence of the clinical impact of this technology. In many patients, a definitive diagnosis can impact not only on information and counseling for their family environment,<sup>39</sup> but also

on active surveillance in search of possible complications, among other types of medical interventions.<sup>37,38</sup> The present data show the usefulness of CMA, allowing improved diagnostic capability with remarkable precision and optimization of the management and supervision of health in this group of patients with special needs.

## Funding

Grant support from Child Health Foundation in Birmingham, Alabama.

## Conflicts of interest

The authors declare to have no conflicts of interest.

## Acknowledgments

The authors are grateful to the Child Health Foundation in Birmingham, Alabama for their grant support for this work, to the participating patients and families, and to Dr. Silvia Castillo and cytogeneticist Ana María Fuentes for review of the conventional karyotype results.

## References

- Christianson A, Howson M, Modell B. March of Dimes: global report on birth defects. The hidden toll of dying and disabled children. White Plains, NY: March of Dimes Birth Defects Foundation; 2006.
- Kumar P, Burton BK. Dysmorphology. In: Kumar P, Burton BK, editors. Congenital malformations: evidence-based evaluation and management. New York: McGraw-Hill Prof Med/Tech; 2007. p. 3–11.
- Rauch A, Hoyer J, Guth S, Zweier C, Kraus C, Becker C, et al. Diagnostic yield of various genetic approaches in patients with unexplained developmental delay or mental retardation. *Am J Med Genet A*. 2006;140:2063–74.
- Vermeesch JR, Fiegler H, de Leeuw N, Szuhai K, Schoumans J, Ciccone R, et al. Guidelines for molecular karyotyping in constitutional genetic diagnosis. *Eur J Hum Genet*. 2007;15:1105–14.
- Hochstenbach R, van Binsbergen E, Engelen J, Nieuwint A, Polstra A, Poddighe P, et al. Array analysis and karyotyping: workflow consequences based on a retrospective study of 36,325 patients with idiopathic developmental delay in the Netherlands. *Eur J Med Genet*. 2009;52:161–9.
- Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. *Am J Hum Genet*. 2010;86:749–64.
- Manning M, Hudgins L. Professional Practice and Guidelines Committee. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. *Genet Med*. 2010;12:742–5.
- Shaffer LG, Ledbetter DH, Lupski JR. Molecular cytogenetics of contiguous gene syndromes: mechanisms and consequences of gene dosage imbalance. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, et al., editors. The metabolic and molecular basis of inherited disease. New York: McGraw Hill; 2001. p. 1291–324.
- Trask BJ. Human cytogenetics: 46 chromosomes, 46 years and counting. *Nat Rev Genet*. 2002;3:769–78.
- Salman M, Jhanwar SC, Ostrer H. Will the new cytogenetics replace the old cytogenetics? *Clin Genet*. 2004;66:265–75.
- Smeets DF. Historical prospective of human cytogenetics: from microscope to microarray. *Clin Biochem*. 2004;37:439–46.
- Turleau C, Vekemans M. New developments in cytogenetics. *Med Sci (Paris)*. 2005;21:940–6.
- Edelmann L, Hirschhorn K. Clinical utility of array CGH for the detection of chromosomal imbalances associated with mental retardation and multiple congenital anomalies. *Ann N Y Acad Sci*. 2009;1151:157–66.
- Jehee FS, Takamori JT, Medeiros PF, Pordeus AC, Latini FR, Bertola DR, et al. Using a combination of MLPA kits to detect chromosomal imbalances in patients with multiple congenital anomalies and mental retardation is a valuable choice for developing countries. *Eur J Med Genet*. 2011;54:e425–32.
- Lee C, Iafrate AJ, Brothman AR. Copy number variations and clinical cytogenetic diagnosis of constitutional disorders. *Nat Genet*. 2007;39:S48–54.
- Shaffer LG, Bejjani BA, Torchia B, Kirkpatrick S, Coppinger J, Ballif BC. The identification of microdeletion syndromes and other chromosome abnormalities: cytogenetic methods of the past, new technologies for the future. *Am J Med Genet C Semin Med Genet*. 2007;145C:335–45.
- Schluth-Bolard C, Till M, Ederly P, Sanlaville D. New chromosomal syndromes. *Pathol Biol (Paris)*. 2008;56:380–7.
- Slavotinek AM. Novel microdeletion syndromes detected by chromosome microarrays. *Hum Genet*. 2008;124:1–17.
- International Collaboration for Clinical Genomics (ICCG). International Standard Cytogenomic Array (ISCA) Consortium Database Search. [cited 4 March 2014]. Available from: <http://www.iccg.org/>
- MacDonald JR, Ziman R, Yuen RK, Feuk L, Scherer SW. The Database of Genomic Variants: a curated collection of structural variation in the human genome. *Nucleic Acids Res*. 2014;42:D986–92.
- Database of Genomic Variants (DGV). [cited 4 March 2014]. Available from: <http://dgv.tcag.ca/dgv/app/home>
- Online Mendelian Inheritance in Man, OMIM®. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD). [cited 10 March 2014]. Available from: <http://omim.org/>
- Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan D, et al. DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. *Am J Hum Genet*. 2009;84:524–33.
- Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources (DECIPHER). [cited 10 March 2014]. Available from: <https://decipher.sanger.ac.uk/>
- European Cytogeneticists Association Register of Unbalanced Chromosome Aberrations (ECARUCA). [cited 10 March 2014]. Available from: <http://umcecaruca01.extern.umcn.nl:8080/ecaruca/ecaruca.jsp>
- de Leeuw N, Dijkhuizen T, Hehir-Kwa JY, Carter NP, Feuk L, Firth HV, et al. Diagnostic interpretation of array data using public databases and internet sources. *Hum Mutat*. 2012.
- Rosenberg C, Knijnenburg J, Bakker E, Vianna-Morgante AM, Sloos W, Otto PA, et al. Array-CGH detection of micro rearrangements in mentally retarded individuals: clinical significance of imbalances present both in affected children and normal parents. *J Med Genet*. 2006;43:180–6.
- Krepischi-Santos AC, Vianna-Morgante AM, Jehee FS, Passos-Bueno MR, Knijnenburg J, Szuhai K, et al. Whole-genome array-CGH screening in undiagnosed syndromic patients: old syndromes revisited and new alterations. *Cytogenet Genome Res*. 2006;115:254–61.
- Michelson DJ, Shevell MI, Sherr EH, Moeschler JB, Gropman AL, Ashwal S. Evidence report: Genetic and metabolic testing on children with global developmental delay: report of the Quality

- Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. *Neurology*. 2011;77:1629–35.
30. Uetani N, Kato K, Ogura H, Mizuno K, Kawano K, Mikoshiba K, et al. Impaired learning with enhanced hippocampal long-term potentiation in PTPdelta-deficient mice. *EMBO J*. 2000;19:2775–85.
  31. Takahashi H, Craig AM. Protein tyrosine phosphatases PTP $\delta$ , PTP $\sigma$ , and LAR: presynaptic hubs for synapse organization. *Trends Neurosci*. 2013;36:522–34.
  32. Bui TH, Vetro A, Zuffardi O, Shaffer LG. Current controversies in prenatal diagnosis 3: is conventional chromosome analysis necessary in the post-array CGH era? *Prenat Diagn*. 2011;31:235–43.
  33. Mason-Suares H, Kim W, Grimmert L, Williams ES, Horner VL, Kunig D, et al. Density matters: comparison of array platforms for detection of copy-number variation and copy-neutral abnormalities. *Genet Med*. 2013;15:706–12.
  34. Wordsworth S, Buchanan J, Regan R, Davison V, Smith K, Dyer S, et al. Diagnosing idiopathic learning disability: a cost-effectiveness analysis of microarray technology in the National Health Service of the United Kingdom. *Genomic Med*. 2007;1:35–45.
  35. Newman WG, Hamilton S, Ayres J, Sanghera N, Smith A, Gaunt L, et al. Array comparative genomic hybridization for diagnosis of developmental delay: an exploratory cost-consequences analysis. *Clin Genet*. 2007;71:254–9.
  36. Trakadis Y, Shevell M. Microarray as a first genetic test in global developmental delay: a cost-effectiveness analysis. *Dev Med Child Neurol*. 2011;53:994–9.
  37. Coulter ME, Miller DT, Harris DJ, Hawley P, Picker J, Roberts AE, et al. Chromosomal microarray testing influences medical management. *Genet Med*. 2011;13:770–6.
  38. Riggs E, Wain K, Riethmaier D, Smith-Packard B, Faucett W, Hoppman N, et al. Chromosomal microarray impacts clinical management. *Clin Genet*. 2013.
  39. Pina-Neto JM. Genetic counseling. *J Pediatr (Rio J)*. 2008;84:S20–6.